Pidontas Corp.

Pidontas is a startup biotechnology company which specializes in providing innovative gene therapies for patients suffering from tauopathy-induced neurodegeneration. Alzheimer's disease (AD) is the current leading cause of neurodegenerative disease and is currently the sixth leading cause of death in the United States. It is projected that by 2030, about 1 in 5 adults over the age of 65 will develop AD, thus there is a critical need to develop new and effective treatments. The immediate project ahead of us involves a series of proof-of-concept studies to provide evidence that retrotransposon expression drives intra-cellular mechanisms of tauopathy. Once the proof-of-concept experiments are completed, we plan on designing an optimized molecule, guided by transposons, to not only halt disease progression but also to regenerate the afflicted neurons. Initial in vitro proof-of-concept experiments are projected to last for 12-14 months, then immediately afterwards we plan on conducting in vivo proof-of-concept studies which should take up to an additional 12 months. Upon completion of both in vitro/in vivo studies, we plan on filing for IND approval to help bring our constructed molecule to clinical trials in which safety and efficacy in humans will be of primary concern . 

The Pidontas team consists of two intelligent and highly motivated MS graduates from the USC Stem Cell Department as the leaders of the research and development team. In addition to R&D, the Pidontas Chief Financial Officer touts years of experience in finance and investment banking. Our advisors hold decades of experience in the biotechnology industry, having earned PhDs and served on advisory/executive boards for several different biotech companies including companies such as Kodikaz Therapeutic Solutions. 

Pidontas not only plans on directly treating tauopathy-induced neurodegeneration, but we also plan on expanding out to other areas of neurological disease such as traumatic brain injury-induced neurodegeneration. Join our endeavor by having a conversation with us, we would be happy to discuss any additional details!